retatrutide phase 2 nejm weight loss 48 weeks percent triple agonist Peptide Series #3 — 🧬🏃🏻‍♀️ BOOM🔥! The most POWERFUL DRUG EVER tested in a clinical trial retatrutide phase 2 nejm 2023

These programs tend to prioritize diet and exercise, but other treatments are sometimes discussed, including weight-loss medications

This is where physician-guided care matters

This question is increasingly circulating in biohacking and peptide communities, but the honest clinical answer is clear: there is no published evidence, pharmacokinetic data, or regulatory guidance supporting this combination

In a Phase 2 trial published in 2023, adults with obesity who received retatrutide weekly for 48 weeks lost up to 24.2% of their body weight on the highest dose nearly a quarter of their weight on average

Solid-phase peptide synthesis strings these amino acid residues together in exact order, yielding a molecular weight of 1419.5 Daltons